-+ 0.00%
-+ 0.00%
-+ 0.00%

Metagenomi targets 2027 clinical trial start for hemophilia A genome-editing candidate MGX-001

PUBT·08/10/2026 20:25:04
Listen to the news
Metagenomi targets 2027 clinical trial start for hemophilia A genome-editing candidate MGX-001
  • Metagenomi Therapeutics targeted a 4Q 2026 IND filing for MGX-001 in hemophilia A, setting up a potential first-in-human study in 2027.
  • Non-human primate preclinical findings supporting MGX-001 were already presented in scientific posters that won top awards at the 2026 ISTH Congress.
  • IND-enabling work is expected to finish by end-3Q 2026, positioning the program for a global clinical rollout pending regulatory clearance.
  • Cash, cash equivalents, and available-for-sale marketable securities totaled USD 120.7 million at June 30, 2026, with runway projected through 4Q 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metagenomi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342388), on August 10, 2026, and is solely responsible for the information contained therein.